Invesco Pharmaceuticals ETF (PJP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Invesco Pharmaceuticals ETF (PJP) with AI Score 47/100 (Weak). The Invesco Pharmaceuticals ETF seeks capital appreciation by investing in US pharmaceutical companies. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 17, 2026Invesco Pharmaceuticals ETF (PJP) Financial Services Profile
Invesco Pharmaceuticals ETF (PJP) provides targeted exposure to the US pharmaceutical sector through its Dynamic Pharmaceutical Intellidex Index tracking strategy, focusing on companies involved in research, development, and distribution of pharmaceuticals, with a quarterly rebalancing approach based on key investment merit criteria.
Investment Thesis
The Invesco Pharmaceuticals ETF (PJP) offers a focused investment opportunity within the pharmaceutical sector. Its value is driven by the Dynamic Pharmaceutical Intellidex Index, which uses a quantitative approach to select holdings based on factors like price and earnings momentum. The quarterly rebalancing ensures the portfolio remains aligned with current market conditions and investment criteria. A potential catalyst is the ongoing innovation within the pharmaceutical industry, which could drive growth for the companies held within the ETF. However, regulatory changes and patent expirations represent potential risks that could impact the performance of the underlying holdings. With a beta of 0.61, PJP exhibits lower volatility compared to the broader market, potentially appealing to risk-averse investors seeking exposure to the pharmaceutical sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.30 billion, indicating a relatively small size within the ETF landscape.
- Beta of 0.61, suggesting lower volatility compared to the overall market.
- The fund invests at least 90% of its assets in stocks within the Dynamic Pharmaceutical Intellidex Index.
- Morningstar rating of 4 stars overall as of August 31, 2025, reflecting solid risk-adjusted performance.
- Holdings are rebalanced and reconstituted quarterly, ensuring the portfolio remains aligned with the index methodology.
Competitors & Peers
Strengths
- Targeted exposure to the US pharmaceutical sector.
- Systematic investment approach based on the Dynamic Pharmaceutical Intellidex Index.
- Quarterly rebalancing to maintain alignment with the index.
- Established brand name of Invesco.
Weaknesses
- Sector-specific focus may lead to higher volatility compared to broader market ETFs.
- Performance is dependent on the performance of the underlying pharmaceutical companies.
- Index methodology may not always capture the best-performing stocks.
- Subject to regulatory and political risks affecting the pharmaceutical industry.
Catalysts
- Ongoing: Pharmaceutical innovation and drug development driving growth for underlying holdings.
- Ongoing: Increasing healthcare spending and aging populations boosting demand for pharmaceutical products.
- Upcoming: Quarterly rebalancing of the Dynamic Pharmaceutical Intellidex Index in May 2026, potentially leading to portfolio adjustments.
- Upcoming: Potential mergers and acquisitions within the pharmaceutical industry, creating value for shareholders.
Risks
- Potential: Regulatory changes and drug pricing pressures impacting pharmaceutical company profitability.
- Potential: Patent expirations and generic competition eroding market share for branded drugs.
- Potential: Economic downturns reducing healthcare spending and demand for pharmaceutical products.
- Ongoing: Competition from other healthcare and pharmaceutical ETFs.
- Ongoing: Dependence on the performance of a specific sector, leading to potential concentration risk.
Growth Opportunities
- Increased Healthcare Spending: The global healthcare expenditure is projected to continue its upward trajectory, driven by aging populations and increasing prevalence of chronic diseases. This trend is expected to boost demand for pharmaceutical products and services, benefiting the companies held within the Invesco Pharmaceuticals ETF. The global healthcare market is estimated to reach trillions of dollars in the coming years, providing a significant growth opportunity for the pharmaceutical sector.
- Drug Development and Innovation: The pharmaceutical industry is characterized by continuous innovation and the development of new drugs and therapies. Breakthroughs in areas such as gene therapy, immunotherapy, and targeted drug delivery have the potential to drive significant growth for pharmaceutical companies. The Invesco Pharmaceuticals ETF, by investing in companies engaged in research and development, is positioned to benefit from these advancements.
- Emerging Markets Expansion: Emerging markets represent a significant growth opportunity for pharmaceutical companies. As these economies develop and healthcare infrastructure improves, demand for pharmaceuticals is expected to increase. Companies held within the Invesco Pharmaceuticals ETF that have a strong presence in emerging markets are likely to experience higher growth rates.
- Aging Population: The global population is aging, with a growing proportion of individuals aged 65 and older. This demographic shift is driving increased demand for healthcare services and pharmaceutical products, particularly those related to age-related diseases. The Invesco Pharmaceuticals ETF, with its focus on pharmaceutical companies, is well-positioned to capitalize on this trend.
- Mergers and Acquisitions: The pharmaceutical industry is characterized by frequent mergers and acquisitions, as companies seek to expand their product portfolios, gain access to new technologies, and achieve economies of scale. These transactions can create value for shareholders and drive growth for the companies involved. The Invesco Pharmaceuticals ETF may benefit from M&A activity within the pharmaceutical sector.
Opportunities
- Growth in the pharmaceutical industry driven by aging populations and increasing healthcare spending.
- Innovation in drug development and biotechnology.
- Expansion into emerging markets.
- Potential for increased investor interest in sector-specific ETFs.
Threats
- Regulatory changes and drug pricing pressures.
- Patent expirations and generic competition.
- Economic downturns and reduced healthcare spending.
- Competition from other healthcare and pharmaceutical ETFs.
Competitive Advantages
- Established Index Tracking: The fund benefits from tracking the Dynamic Pharmaceutical Intellidex Index, which provides a systematic approach to stock selection.
- Brand Recognition: Invesco is a well-known asset management firm, providing credibility and investor trust.
- Focused Sector Exposure: The fund offers targeted exposure to the pharmaceutical sector, which can be attractive to investors seeking specific industry exposure.
About PJP
The Invesco Pharmaceuticals ETF (PJP) is designed to provide investors with targeted exposure to the United States pharmaceutical industry. Launched by Invesco, a well-established asset management firm, the ETF operates by tracking the Dynamic Pharmaceutical Intellidex Index. This index employs a quantitative methodology to select and weight its holdings, focusing on factors such as price momentum, earnings momentum, quality, management action, and value. The fund invests at least 90% of its total assets in the common stocks that comprise the Index. The ETF's portfolio consists of approximately 30 US pharmaceutical companies that are principally engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. This targeted approach allows investors to gain specific exposure to the pharmaceutical sector without the need to individually select stocks. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November. As of August 31, 2025, the Fund had an overall rating of 4 stars out of 164 funds, according to Morningstar. The fund was rated 5 stars out of 164 funds for the 3-year period, 5 stars out of 151 funds for the 5-year period, and 2 stars out of 118 funds for the 10-year period.
What They Do
- Invests in a portfolio of US pharmaceutical companies.
- Tracks the Dynamic Pharmaceutical Intellidex Index.
- Rebalances its portfolio quarterly to maintain alignment with the index.
- Focuses on companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals.
- Provides investors with targeted exposure to the pharmaceutical sector.
- Aims to provide capital appreciation through its investment strategy.
Business Model
- The fund generates revenue through management fees charged to investors.
- The fund's performance is directly linked to the performance of the underlying pharmaceutical stocks.
- The Dynamic Pharmaceutical Intellidex Index guides the fund's investment decisions.
Industry Context
The Invesco Pharmaceuticals ETF operates within the asset management industry, specifically targeting the pharmaceutical sector. The pharmaceutical industry is characterized by high research and development costs, stringent regulatory oversight, and patent protection. The ETF's performance is closely tied to the performance of the US pharmaceutical market, which is influenced by factors such as drug approvals, healthcare policy changes, and demographic trends. Competitors in the asset management space offer a variety of healthcare and pharmaceutical ETFs, requiring PJP to differentiate itself through its index methodology and investment strategy.
Key Customers
- Individual investors seeking exposure to the pharmaceutical sector.
- Institutional investors looking for a targeted investment in US pharmaceutical companies.
- Financial advisors seeking to diversify client portfolios with a sector-specific ETF.
Financials
Chart & Info
Invesco Pharmaceuticals ETF (PJP) stock price: Price data unavailable
Latest News
-
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial
benzinga · Feb 17, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PJP.
Price Targets
Wall Street price target analysis for PJP.
MoonshotScore
What does this score mean?
The MoonshotScore rates PJP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
PJP Financial Services Stock FAQ
What does Invesco Pharmaceuticals ETF do?
The Invesco Pharmaceuticals ETF (PJP) is designed to track the performance of the Dynamic Pharmaceutical Intellidex Index, providing investors with targeted exposure to the US pharmaceutical sector. The fund invests at least 90% of its total assets in the common stocks that comprise the Index. This index uses a quantitative methodology to select and weight its holdings, focusing on factors such as price momentum, earnings momentum, quality, management action, and value. The ETF offers a way to invest in a basket of approximately 30 US pharmaceutical companies without needing to select individual stocks.
What do analysts say about PJP stock?
AI analysis is pending for PJP. Generally, ETFs like PJP are evaluated based on the performance of their underlying holdings, expense ratios, and tracking efficiency. The pharmaceutical sector is influenced by factors such as drug approvals, regulatory changes, and demographic trends. Investors may want to evaluate these factors when evaluating the potential risks and returns of PJP. PJP's performance is tied to the success of the pharmaceutical companies it holds, and its value may fluctuate based on market conditions and industry-specific events.
What are the main risks for PJP?
The Invesco Pharmaceuticals ETF (PJP) is subject to several risks inherent in the pharmaceutical sector. Regulatory changes, such as drug pricing policies, can significantly impact the profitability of pharmaceutical companies. Patent expirations can lead to increased competition from generic drugs, reducing revenue for branded drug manufacturers. Economic downturns can reduce healthcare spending, affecting demand for pharmaceutical products. Additionally, the ETF is exposed to market risk, as its value can fluctuate based on overall market conditions and investor sentiment towards the pharmaceutical sector.
What are the key factors to evaluate for PJP?
Invesco Pharmaceuticals ETF (PJP) currently holds an AI score of 47/100, indicating low score. Key strength: Targeted exposure to the US pharmaceutical sector.. Primary risk to monitor: Potential: Regulatory changes and drug pricing pressures impacting pharmaceutical company profitability.. This is not financial advice.
How frequently does PJP data refresh on this page?
PJP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PJP's recent stock price performance?
Recent price movement in Invesco Pharmaceuticals ETF (PJP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Targeted exposure to the US pharmaceutical sector.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PJP overvalued or undervalued right now?
Determining whether Invesco Pharmaceuticals ETF (PJP) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PJP?
Before investing in Invesco Pharmaceuticals ETF (PJP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for PJP, limiting the depth of some sections.
- Reliance on Morningstar ratings as of August 31, 2025, which may not reflect current performance.